Correction to the press release regarding sales milestone payments in Europe in connection with the new Licensing Agreement with ProStrakan

04.08.08 - 22:36 ... source : Orexo

...  The potential sales milestone payments in Europe in connection with the new agreement with ProStrakan amount to 19.9 MEUR and not 29.9 MEUR as announced in the previous press release from today.    For more information, please contact: Claes Wenthzel, Executive Vice President & CFO, Orexo ABTel: +46 (0)708-62 01 22E-mail: claes.wenthzel@orexo.com   TO THE EDITORS About Orexo  Orexo is a pharmaceutical company, focusing on development of new, patented drugs by combining well-documented substances with innovative technologies, and the development of new treatments ...» Next (HTML)